Isolated liver perfusion for liver metastases: pharmacokinetic advantage?
The pharmacokinetic advantage of a novel system to noninvasively isolate the hepatic venous outflow and infuse high doses of chemotherapy (doxorubicin or 5-FU) is discussed and compared with intravenous infusion and intra-arterial infusion without hepatic venous detoxification. This dose intensification schema may provide new pharmacokinetic and pharmacodynamic principles for the treatment of a variety of tumors metastasizing the liver, including melanoma, sarcoma, and adenocarcinoma.
Ravikumar
T S
TS
Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
Dixon
K
K
D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D010478:Chemotherapy, Cancer, Regional Perfusion; D004317:Doxorubicin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005472:Fluorouracil / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D006503:Hepatic Veins; D006801:Humans; D007269:Injections, Intra-Arterial; D007275:Injections, Intravenous; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary; D012509:Sarcoma / Q000188:drug therapy / Q000556:secondary
D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D004317:Doxorubicin; D005472:Fluorouracil